Carlos F. Tirado

Carlos F. Tirado

Auto-generated profile, based on publicly available information

Carlos F. Tirado

Chief Medical Officer, CARMAhealth PLLC, Austin, Texas

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Mental Health Clinician
Verified
Journal Article
Open access
MRMandy L. Renfro
Mandy L. Renfro
LLLindsey J Loera
Lindsey J Loera
CTCarlos F. Tirado
Carlos F. Tirado
LHLucas Hill
Lucas Hill
Introduction: Maintaining abstinence through the opioid withdrawal period is a substantial barrier to treatment for patients with opioid use disorder. The alpha-2 agonist lofexidine has demonstrated efficacy and safety in clinical trials, but pragmatic studies describing its use in clinical practice are lacking. This case series describes the use of lofexidine for opioid withdrawal symptoms in an inpatient addiction treatment facility. Methods: Seventeen patients receiving at least 1 dose of lofexidine during inpatient treatment for opioid withdrawal were included in this study. A retrospective chart review was conducted for clinical, subjective, and objective data. Adverse events, total daily dose, clinical opioid withdrawal scale (COWS) scores, vital signs, and reasons for early discontinuation of lofexidine are reported. Results: Patients treated with lofexidine experienced mild withdrawal symptoms throughout treatment. Most patients (65%) experienced a decrease in their average daily COWS scores from intake to discharge. Two patients (12%) left treatment against medical advice, and 5 patients (29%) discontinued treatment prior to day 7 due to resolution of symptoms. Average daily blood pressure readings remained stable, and daily average heart rate decreased over time. Discussion: Lofexidine can be successfully incorporated into a conventional withdrawal management protocol. The cost of lofexidine and its recent introduction to the market remain barriers to accessibility in the United States. Studies evaluating patient-reported outcomes as well as direct comparisons with other alpha-2 agonists are needed to inform optimal clinical use of lofexidine.

20 July 2009
Verified
Dataset
Closed access
BABryon Adinoff
Bryon Adinoff
CTCarlos Tirado
Carlos Tirado
This article examines the role of brain-derived neurotrophic factor (BDNF) in a part of the mesolimbic reward system important for the development of drug dependence. This article demonstrates that BDNF can induce behavioral and neuroanatomical alterations resembling opiate-dependent states in non-dependent animals. All major drugs of abuse share the characteristic of causing changes in regions of the mesolimbic reward system, the ventral tegmental area (VTA) and nucleus accumbens (NAc), that drive downstream changes in memory, learning and higher cognitive function. These changes then favor the continued use of the drug over other natural rewards. This article expands our understanding of the important role BDNF has in the development of dependence-like reward states. The authors conducted a series of five experiments testing levels of BDNF/mRNA in the VTA, the specific effect of BDNF on opioid reward, the anatomic reward pathway influenced by BDNF, and BDNF's potential role in changing GABA-A receptor activity. The experiments showed that BDNF, when infused directly into the VTA of non-dependent rats, led to behavioral and neuroanatomical changes favoring a shift toward a dopamine (DA)-dependent reward pathway. Similar changes are commonly seen in drug-dependent states. Furthermore, BDNF activity in VTA is also associated with a switch in the GABA-A receptor activity from inhibitory to excitatory. Although this study was performed in rodents, the findings have important clinical implications. Compounds that selectively inhibit BDNF activity in the mesolimbic reward system may have important therapeutic applications in substance use disorders. Synthetic opioid analgesics that do not induce this BDNF-mediated switch from DA-independent to DA-dependent reward could greatly enhance the safety of chronic opioid analgesia. Identification of human polymorphisms that are associated with abnormally high levels of BDNF induced by drugs of abuse could help screen individuals at high risk for drug addiction. Further research is required to further elucidate the role of BDNF in the pathogenesis of drug addiction and for the development of therapeutic agents that prevent or reverse the switch to a drug-dependent state.